<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006540</article-id><article-id pub-id-type="pmc">PMC11859895</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020173</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00173</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Targeted Elimination of Influenza Virus and Infected Cells with Near-Infrared Antiviral Photoimmunotherapy (NIR-AVPIT)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mizukoshi</surname><given-names>Terumi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceutics-17-00173" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Tateishi</surname><given-names>Koichiro</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af2-pharmaceutics-17-00173" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Tokusanai</surname><given-names>Mizuki</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af2-pharmaceutics-17-00173" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Yoshinaka</surname><given-names>Yoshiyuki</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-pharmaceutics-17-00173" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Yamamoto</surname><given-names>Aisaku</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceutics-17-00173" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Yamamoto</surname><given-names>Naoki</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceutics-17-00173" ref-type="aff">1</xref><xref rid="af3-pharmaceutics-17-00173" ref-type="aff">3</xref><xref rid="c1-pharmaceutics-17-00173" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Yamamoto</surname><given-names>Norio</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-pharmaceutics-17-00173" ref-type="aff">2</xref><xref rid="c1-pharmaceutics-17-00173" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Consalvi</surname><given-names>Sara</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00173"><label>1</label>Medical Corporation Koujunkai, Kawasaki 211-0063, Japan; <email>momo.mizukoshi@nifty.com</email> (T.M.); <email>kosugihifuka@gmail.com</email> (A.Y.)</aff><aff id="af2-pharmaceutics-17-00173"><label>2</label>Department of Microbiology, Tokai University School of Medicine, Isehara 259-1193, Japan; <email>tateishi.koichiro.f@tokai.ac.jp</email> (K.T.); <email>2cmud015@mail.u-tokai.ac.jp</email> (M.T.); <email>twoyoshi@outlook.com</email> (Y.Y.)</aff><aff id="af3-pharmaceutics-17-00173"><label>3</label>Genome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa 272-8516, Japan</aff><author-notes><corresp id="c1-pharmaceutics-17-00173"><label>*</label>Correspondence: <email>lb-20yamamoto@hospk.ncgm.go.jp</email> (N.Y.); <email>n-yamamoto@tokai.ac.jp</email> (N.Y.)</corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>173</elocation-id><history><date date-type="received"><day>16</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>03</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background</bold>: Seasonal influenza causes significant morbidity and mortality each year. Since viruses can easily acquire drug-resistant mutations, it is necessary to develop new antiviral strategies with different targets. Near-infrared photoimmunotherapy (NIR-PIT) is a type of anti-cancer therapy that has recently attracted considerable attention, with favorable outcomes reported for several cancers. In this study, we investigated whether this approach could be used as a novel anti-influenza therapy to destroy influenza virus and infected cells. <bold>Methods</bold>: To evaluate the efficacy of near-infrared antiviral photoimmunotherapy (NIR-AVPIT), we prepared an anti-hemagglutinin (HA) monoclonal antibody without neutralizing activity against influenza A virus (FluV) labeled with IR-700 and reacted it with FluV and infected cells, as well as HA-expressing HEK293 cells. <bold>Results</bold>: NIR-AVPIT strongly inactivated FluV virions, suppressed cytopathic effects, and achieved more than a 4-log reduction in viral RNA amplification. Treatment of FluV-infected cells with the antibody-IR700 complex and NIR in the early stages of infection significantly inhibited viral propagation, and double treatment with time apart exerted a greater inhibitory effect. NIR-AVPIT rapidly induced morphological changes in HA-expressing HEK293 cells and inhibited the proliferation of these cells. <bold>Conclusions</bold>: These results suggest that NIR-AVPIT targeting HA antigens could inactivate FluV and eliminate infected cells in vitro. This strategy is a promising approach to treat various viral infections, including influenza. </p></abstract><kwd-group><kwd>influenza virus</kwd><kwd>hemagglutinin</kwd><kwd>near-infrared</kwd><kwd>IR-700</kwd><kwd>monoclonal antibody</kwd></kwd-group><funding-group><award-group><funding-source>JSPS KAKENHI</funding-source><award-id>19K08962</award-id></award-group><award-group><funding-source>Research and Study Project of Tokai University</funding-source><award-id>PJ2021-02</award-id></award-group><award-group><funding-source>Tokai University School of Medicine</funding-source><award-id>2021-01</award-id></award-group><funding-statement>This work was funded by JSPS KAKENHI grant number 19K08962, Research and Study Project of Tokai University grant number PJ2021-02, and Tokai University School of Medicine Project Research grant number 2021-01 to Norio Yamamoto.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00173"><title>1. Introduction</title><p>Approximately a billion people worldwide are infected with the influenza virus (FluV) each year, of which 3&#x02013;5 million people become seriously ill and 290,000&#x02013;650,000 people die from the associated respiratory symptoms [<xref rid="B1-pharmaceutics-17-00173" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-17-00173" ref-type="bibr">2</xref>]. The highest mortality rates were estimated in sub-Saharan Africa, southeast Asia, and among people aged 75 years or older [<xref rid="B1-pharmaceutics-17-00173" ref-type="bibr">1</xref>] (Iuliano et al., 2018). Antiviral drugs targeting proteins and enzymes encoded by viral genes (e.g., M2 protein, neuraminidase, RNA polymerase, and cap-dependent endonuclease) are available for the treatment of FluV infection but are often ineffective if not used within approximately 48 h after symptom onset [<xref rid="B3-pharmaceutics-17-00173" ref-type="bibr">3</xref>]. Studies have also reported that the early resolution of symptoms with antiviral drugs does not provide sufficient immunity [<xref rid="B4-pharmaceutics-17-00173" ref-type="bibr">4</xref>]. Furthermore, many protective antibodies against FluV are known to bind to hemagglutinin (HA) on the surface of the virus [<xref rid="B5-pharmaceutics-17-00173" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-17-00173" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-17-00173" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-17-00173" ref-type="bibr">8</xref>], but the virus readily escapes from neutralizing antibodies through mutations, making it difficult to develop effective antibody therapies. Therefore, new approaches for treating FluV infections are in high demand. </p><p>Near-infrared photoimmunotherapy (NIR-PIT) is a new cancer therapy in which a specific antibody conjugated to the sensitizer IRDye700DX (IR700) is administered to target cells. NIR irradiation induces a structural change in the antibody-IR700 conjugate and causes mechanical stress at the antibody binding site, resulting in cell death due to cytoplasmic leakage [<xref rid="B9-pharmaceutics-17-00173" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceutics-17-00173" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-17-00173" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceutics-17-00173" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-17-00173" ref-type="bibr">13</xref>]. Importantly, the killing of target cells with NIR-PIT is specific, and cells without the antibody-IR700 conjugate are not affected. Moreover, no severe adverse effects have been reported in the clinical use of NIR-PIT. Therefore, NIR-PIT is expected to be a potential new strategy for the treatment of cancer. </p><p>NIR can selectively damage cancer cells expressing a specific antigen by administering antibody-IR700 complexes. However, infectious diseases may be more suitable targets for this technology than cancers due to the pathologically high expression of the foreign antigens of the causative organisms in patients with infectious diseases. In fact, photoimmunotherapy has begun to be applied to viral infections [<xref rid="B14-pharmaceutics-17-00173" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-17-00173" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-17-00173" ref-type="bibr">16</xref>], but what factors influence its efficacy have not yet been fully analyzed. In this study, we developed a new antiviral strategy called near-infrared antiviral photoimmunotherapy (NIR-AVPIT) and selected the influenza A (H1N1)pdm09 virus, which caused a pandemic in 2009 [<xref rid="B17-pharmaceutics-17-00173" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-17-00173" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-17-00173" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-17-00173" ref-type="bibr">20</xref>], as the first target to test NIR-AVPIT. The effects of NIR-AVPIT on free virion and FluV-infected cells as well as the relationship between antiviral efficacy and time of post-infection were evaluated.</p></sec><sec id="sec2-pharmaceutics-17-00173"><title>2. Materials and Methods</title><sec id="sec2dot1-pharmaceutics-17-00173"><title>2.1. Cells</title><p>Madin&#x02013;Darby Canine Kidney (MDCK) and HEK293 cells were purchased from American Type Culture Collection (ATCC; Rockville, MD, USA). MDCK and HA-expressing HEK 293 cells were cultured in Dulbecco&#x02019;s Modified Eagle&#x02019;s Medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 1 g/L D-glucose, 4 mM L-glutamine, 10% fetal bovine serum (FBS; Thermo Fisher Scientific), and 1% penicillin/streptomycin (Thermo Fisher Scientific). All cells were grown in a humidified atmosphere of 5% CO<sub>2</sub> at 37 &#x000b0;C.</p></sec><sec id="sec2dot2-pharmaceutics-17-00173"><title>2.2. Plasmid Construction</title><p>A codon-optimized HA of influenza virus A/California/7/2009 (H1N1pdm09, GISAID EpiFlu database, EPI_ISL_31553) was synthesized by Eurofins Genomics (Tokyo, Japan). The PCR-amplified fragment of the HA-coding region was inserted into a pBApo-EF1&#x003b1;-puro vector (Takara Bio, Shiga, Japan) using an In-Fusion HD cloning kit (Takara Bio). The constructed plasmid, pBApo-EF1&#x003b1;-HA-puro, was used for the expression of HA in HEK293 cells.</p></sec><sec id="sec2dot3-pharmaceutics-17-00173"><title>2.3. Generation of Monoclonal Antibodies</title><p>The influenza virus A/California/7/2009 was propagated in embryonated chicken eggs and purified using sucrose gradient (10%&#x02013;50%) ultracentrifugation. To prepare the ether-split antigen, the purified virus was mixed with an equal volume of ether and incubated at room temperature for 1 h with stirring. The mixture was centrifuged at 3000 rpm for 15 min to separate the aqueous and ether phases and the aqueous phase was collected. The HA antigen was obtained after two rounds of purification. Following a one-week acclimatization period, three 8-week-old female B6D2F1 mice were immunized with purified HA proteins. To increase the success rate of obtaining monoclonal antibodies, three mice were used for immunization. Splenocytes of the mice were fused with myeloma cells 4 weeks after immunization, and 800 wells of hybridoma cells were seeded. The supernatants were screened for reactivity using ELISA with HA antigen as the target and BSA as a negative control. Wells were considered positive if the OD difference between HA and BSA exceeded 0.05. Finally, three hybridoma cell clones were established to produce monoclonal antibodies (mAb1, mAb2, and mAb3) reactive to the HA protein. The culture medium of each hybridoma clone was centrifuged at 7000 rpm for 20 min and the antibodies were purified using AcroSep Hyper DF columns (Pall Corporation, Port Washington, NY, USA). The concentrations of purified monoclonal antibodies were measured using a BCA protein assay kit (Thermo Fisher Scientific). The immunoglobulins were characterized using a mouse immunoglobulin isotyping ELISA kit (BD Pharmingen, Franklin Lakes, NJ, USA).</p></sec><sec id="sec2dot4-pharmaceutics-17-00173"><title>2.4. Selection of the Anti-HA Monoclonal Antibody Without Neutralizing Activity</title><p>The three monoclonal antibodies at 1 &#x000b5;g/mL and 10 &#x000b5;g/mL concentrations and FluV (2 &#x000d7; 10<sup>4</sup> pfu/mL) were incubated at room temperature for 1 h, and 100 &#x000b5;L of the mixture was added to MDCK cells in a 96-well plate. The cells were incubated at 37 &#x000b0;C for 48 h, and cell morphology was observed under an optical microscope CKX31 (Olympus, Tokyo, Japan). The amount of viral RNA in the culture supernatant at 48 h post-infection (hpi) was determined using RT-qPCR (reverse transcription quantitative PCR). </p></sec><sec id="sec2dot5-pharmaceutics-17-00173"><title>2.5. Generation of HA-Expressing HEK293 Cells</title><p>The pBApo-EF1&#x003b1;-HA-puro vector was digested with ScaI (New England Biolabs, Ipswich, MA, USA) and HEK293 cells were transfected with linearized pBApo-EF1&#x003b1;-HA-puro using Lipofectamine 2000 (Thermo Fisher Scientific). Puromycin-resistant cells were cloned using the limiting-dilution method and clones with high cell-surface expression of HA were identified by fluorescence-activated cell sorting (FACS) analysis with an anti-HA antibody (mAb3) and goat anti-mouse IgG antibody-Alexa Fluor 488 (Abcam, Cambridge, UK) using a BD FACS Calibur Flow Cytometer (BD Biosciences, Franklin Lakes, NJ, USA). </p></sec><sec id="sec2dot6-pharmaceutics-17-00173"><title>2.6. Preparation of IR700-Conjugated Antibody</title><p>mAb3 was conjugated to IR700 using an IRDye 700DX protein labeling kit (LI-COR, Lincoln, NE, USA) following the manufacturer&#x02019;s instructions. Briefly, 100 &#x000b5;g mAb3 was mixed with 0.7 &#x000b5;L IR-dye700 in 0.1 mol/L K<sub>2</sub>HPO<sub>4</sub> (pH 8.5) and incubated at room temperature for 2 h. The dye-labeled antibodies were purified using Pierce Zeba Desalting Spin Columns (Thermo Fisher Scientific). The dye and protein concentrations were measured at 689 and 280 nm, respectively, using a spectrophotometer (NanoDrop 2000c; Thermo Fisher Scientific). The dye/mAb3 ratio was estimated to be 1.5:1.</p></sec><sec id="sec2dot7-pharmaceutics-17-00173"><title>2.7. NIR Irradiation of FluV</title><p>The mixtures containing influenza virus A/Narita/1/2009 (2 &#x000d7; 10<sup>4</sup> pfu/mL) and mAb3-IR700 conjugates (1 &#x000b5;g/mL) were incubated at 37 &#x000b0;C for 1 h and then irradiated with NIR at 60 J/cm<sup>2</sup> using near-infrared equipment (LED S6775, Hamamatsu Photonics, Shizuoka, Japan) for 1 h. Then, 100 &#x000b5;L NIR-irradiated or control mixtures were added to each well of MDCK cells cultured in a 96-well plate. The cells were incubated with the mixtures at 37 &#x000b0;C for 1 h before the culture media containing virus and IR700-labeled mAb3 were exchanged with 100 &#x000b5;L Opti-PRO SFM (Thermo Fisher Scientific) with 4 mM L-glutamine and 2 &#x000b5;g/mL acetylated trypsin. The supernatants were collected for viral quantification after 48 h of incubation. </p></sec><sec id="sec2dot8-pharmaceutics-17-00173"><title>2.8. NIR-Irradiation of HA-Expressing HEK293 Cells</title><p>HEK293 cells with high HA expression were treated with mAb3-IR700 conjugates (1 &#x000b5;g/mL) at 37 &#x000b0;C for 1 h and irradiated with NIR light at 60 J/cm<sup>2</sup> for 1 h. The cell morphology was observed by microscopy 1.5 h and 24 h post-irradiation. </p></sec><sec id="sec2dot9-pharmaceutics-17-00173"><title>2.9. NIR-Irradiation of Virus-Infected Cells</title><p>MDCK cells were seeded in 96-well plates and infected with FluV at 0.1 MOI. At 6 and/or 24 hpi, infected cells were incubated with 1 &#x000b5;g/mL mAb3-IR700 conjugates at 37 &#x000b0;C for 1 h. The cells were irradiated with NIR at 60 J/cm<sup>2</sup> for 1 h and the culture media was replaced with Opti-PRO SFM medium with 4 mM L-glutamine and 2 &#x000b5;g/mL acetylated trypsin. Samples were collected for virus quantification and MDCK cells were observed under a microscope at 24 and/or 48 hpi.</p></sec><sec id="sec2dot10-pharmaceutics-17-00173"><title>2.10. Evaluation of Cell Viability</title><p>The viability of MDCK cells after NIR irradiation was evaluated using the MTS assay kit (CellTiter 96 AQueous One Solution Cell Proliferation Assay; Promega, Madison, WI, USA). Briefly, 20 &#x000b5;L MTS assay solution was added to each well of a 96-well plate containing MDCK cells 48 h after virus inoculation. The cells were incubated for 4 h at 37 &#x000b0;C before the optical density was measured at 490 nm (OD<sub>490</sub>) using a Spark M10 microplate reader (Tecan, M&#x000e4;nnedorf, Switzerland). </p></sec><sec id="sec2dot11-pharmaceutics-17-00173"><title>2.11. RNA Extraction and RT-qPCR</title><p>Viral RNA was extracted using TRI reagent (Molecular Research Center, Inc., Cincinnati, OH, USA) following the manufacturer&#x02019;s instructions. Culture supernatants were collected 24 or 48 h after virus inoculation and mixed with 0.9 mL TRI reagent, including total RNA from uninfected A549 cells as the loading control for normalization. Viral RNA was quantified using the TaqMan Fast Virus 1-step real-time RT-PCR assay kit (Thermo Fisher Scientific) and Quant Studio 3 real-time PCR system (Thermo Fisher Scientific), as described previously [<xref rid="B21-pharmaceutics-17-00173" ref-type="bibr">21</xref>]. The sequences of the primer and probe sets were as follows: FluV-F, 5&#x02032;-CACCTGATATTGTGGATTACTGATCG-3&#x02032;; FluV-R, 5&#x02032;-CACTCTGCTGTTCCTGTTGATATTC-3&#x02032;; FluV-P,&#x02002;5&#x02032;-FAM-CCTCATGGACTCAGGCACTCCTTCCG-TAMRA-3&#x02032;; 18S-F, 5&#x02032;-GTAACCCGTTGAACCCCATT-3&#x02032;; 18S-R, 5&#x02032;-CCATCCAATCGGTAGTAGCG-3&#x02032;; 18S-P, 5&#x02032;-FAM-TGCGTTGATTAAGTCCCTGCCCTTTGTA-TAMRA-3&#x02032;.</p></sec><sec id="sec2dot12-pharmaceutics-17-00173"><title>2.12. Statistical Analysis</title><p>Values are expressed as the mean&#x02009; &#x000b1; &#x02009;standard deviation (SD). Paired Student&#x02019;s <italic toggle="yes">t</italic>-tests were used to assess statistical differences and <italic toggle="yes">p</italic>&#x02009; &#x0003c;&#x02009; 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-17-00173"><title>3. Results</title><sec id="sec3dot1-pharmaceutics-17-00173"><title>3.1. Selection of the Anti-Influenza Virus HA Antibody for NIR-AVPIT</title><p>To create anti-HA antibodies conjugated with IR700 for use in NIR-AVPIT, we tested the neutralizing activity of the three monoclonal antibodies generated (mAb1, mAb2, and mAb3) against HA of FluV. To confirm the virucidal activity of NIR-AVPIT, an HA-specific antibody that lacked neutralizing activity was required. After MDCK cells were infected with FluV in the presence or absence of monoclonal antibodies, a small or no cytopathic effect (CPE) was observed with 10 &#x000b5;g/mL of mAb1 and mAb2, whereas a strong CPE was observed with mAb3 (<xref rid="pharmaceutics-17-00173-f001" ref-type="fig">Figure 1</xref>A). The amount of viral RNA in the culture supernatant was quantified using RT-qPCR, which confirmed that mAb1 and mAb2 significantly inhibited FluV amplification, while mAb3 did not (<xref rid="pharmaceutics-17-00173-f001" ref-type="fig">Figure 1</xref>B). These results indicated that mAb3 had no neutralizing activity and it is suitable for evaluation of NIR-AVPIT. Based on these results, 1 &#x000b5;g/mL mAb3 was used in subsequent experiments.</p></sec><sec id="sec3dot2-pharmaceutics-17-00173"><title>3.2. Direct Inactivation of FluV Virions by NIR-AVPIT</title><p>To evaluate the direct impact of NIR-AVPIT on FluV virions, we inoculated MDCK cells with FluV treated with mAb3-IR700, NIR, or a combination of both, and FluV infection was monitored through CPE analysis and viral RNA quantification by RT-qPCR (<xref rid="pharmaceutics-17-00173-f002" ref-type="fig">Figure 2</xref>A). FluV with mAb3-IR700 or NIR did not inhibit CPE progression, but the combination of mAb3-IR700 and NIR blocked FluV-induced CPE in MDCK cells (<xref rid="pharmaceutics-17-00173-f002" ref-type="fig">Figure 2</xref>B). The amount of viral RNA was significantly decreased after treatment with both mAb3-IR700 and NIR when compared to that of the control at 48 hpi (<xref rid="pharmaceutics-17-00173-f002" ref-type="fig">Figure 2</xref>C). Treatment of FluV with either mAb3-IR700 or NIR did not significantly affect FluV infection. These results demonstrated that NIR-AVPIT directly inactivated FluV virions and prevented FluV infection in MDCK cells. </p></sec><sec id="sec3dot3-pharmaceutics-17-00173"><title>3.3. Effect of NIR-AVPIT Treatment on Virus-Infected Cells and HA-Expressing HEK293 Cells</title><p>Our initial experiments showed that NIR-AVPIT directly damaged FluV. Therefore, we next investigated whether NIR-AVPIT treatment was effective in FluV-infected cells. Since influenza viruses bud from infected cells approximately 6 to 8 h after infection [<xref rid="B22-pharmaceutics-17-00173" ref-type="bibr">22</xref>], FluV-infected MDCK cells were treated with mAb3-IR700 and/or NIR either once (at 7 or 25 hpi) or twice (at 7 and 25 hpi) to evaluate their antiviral effects (<xref rid="pharmaceutics-17-00173-f003" ref-type="fig">Figure 3</xref>A). Cell morphology was observed by optical microscopy at 48 h after virus inoculation. The cells treated with NIR-AVPIT once at 7 hpi and twice at 7 and 25 hpi displayed clear inhibition of CPE at 48 hpi (<xref rid="pharmaceutics-17-00173-f003" ref-type="fig">Figure 3</xref>B). In contrast, a strong CPE was observed in cells subjected to NIR-AVPIT once at 25 hpi. </p><p>Similarly to the results of CPE analysis, viral RNA levels were significantly reduced in the cells treated once (at 7 hpi) with NIR-AVPIT at 24 hpi, and in the cells treated once (at 7 hpi) or twice (at 7 and 25 hpi) with NIR-AVPIT at 48 hpi, when compared with the control cells (<xref rid="pharmaceutics-17-00173-f003" ref-type="fig">Figure 3</xref>C). Moreover, double NIR-AVPIT applications resulted in a significantly stronger inhibition of viral production than a single application of NIR-AVPIT (<xref rid="pharmaceutics-17-00173-f003" ref-type="fig">Figure 3</xref>C). We measured cell viability 48 h after viral inoculation using an MTS assay. Cells with single (at 7 hpi) or double (at 7 and 25 hpi) NIR-AVPIT treatments showed significantly higher viability than the FluV-infected control and showed no reduction in cell viability when compared with the negative control (<xref rid="pharmaceutics-17-00173-f003" ref-type="fig">Figure 3</xref>D). These results indicated that FluV-infected cells were efficiently removed by the combination of mAb3 and NIR irradiation. The effect of NIR-AVPIT on infected cells was lower than that of direct virion inactivation; however, in the early stages of viral infection, NIR-AVPIT was effective in destroying infected cells and inhibiting virus propagation.</p><p>To confirm that NIR-AVPIT specifically targeted the FluV HA protein, HEK293 cell clones expressing HA were generated. FACS analysis indicated that 293-HA clone 3 showed the highest HA expression on the cell surface (<xref rid="pharmaceutics-17-00173-f003" ref-type="fig">Figure 3</xref>E). The 293-HA clone 3 cells were then subjected to mAb3-IR700 treatment and NIR irradiation, followed by microscopic examination of their morphology (<xref rid="pharmaceutics-17-00173-f003" ref-type="fig">Figure 3</xref>F). NIR-AVPIT of 293-HA clone 3 cells induced cell rounding 1.5 h after irradiation and reduced cell proliferation for 24 h when compared to that in the other groups (<xref rid="pharmaceutics-17-00173-f003" ref-type="fig">Figure 3</xref>F). These results demonstrated that NIR treatment with mAb3-IR700 targeted HA proteins and damaged cells that highly expressed these proteins.</p></sec></sec><sec sec-type="discussion" id="sec4-pharmaceutics-17-00173"><title>4. Discussion</title><p>NIR-PIT has been primarily evaluated as a therapy for various tumors, including glioblastoma, breast carcinoma, lung carcinoma, and metastases [<xref rid="B23-pharmaceutics-17-00173" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceutics-17-00173" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-17-00173" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-17-00173" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-17-00173" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-17-00173" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-17-00173" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-00173" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceutics-17-00173" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-17-00173" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-17-00173" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceutics-17-00173" ref-type="bibr">34</xref>]. In the present study, we examined whether NIR-PIT could also be used as a therapy for viral infections. Vaccines and antivirals are the primary measures to combat influenza, COVID-19, and other common viral infections, but their development is fraught with challenges. For example, it generally takes considerable time for vaccines and antivirals to become commercially available, and antigenically drifted or drug-resistant strains of the virus can easily emerge, resulting in a loss of their efficacy. Thus, rapid and effective countermeasures against viral diseases are urgently needed. In this context, NIR-AVPIT targeting a highly conserved epitope among influenza viruses could be a promising solution to address these challenges.</p><p>Neutralizing antibodies can be useful against viral infections [<xref rid="B35-pharmaceutics-17-00173" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-17-00173" ref-type="bibr">36</xref>]. However, to demonstrate the effectiveness of NIR-AVPIT, it is essential to perform NIR-AVPIT using an antibody that lacks neutralizing activity. Therefore, in this study, we first developed an antibody that binds to the virus but has no neutralizing activity. Our results showed that among the three antibodies developed, mAb3 exhibited minimal to no neutralizing activity against FluV, leading to its selection for use at low concentration in subsequent experiments (<xref rid="pharmaceutics-17-00173-f001" ref-type="fig">Figure 1</xref>). </p><p>Next, NIR-AVPIT using mAb3 was evaluated in FluV particles as well as in virus-infected cells. The results showed that FluV virions were strongly inactivated when treated directly with NIR-AVPIT, suggesting its utility in treating FluV (<xref rid="pharmaceutics-17-00173-f002" ref-type="fig">Figure 2</xref>). Furthermore, NIR-AVPIT significantly inhibited FluV amplification and FluV-induced CPE in infected cells and specifically damaged HA-expressing HEK293 cells (<xref rid="pharmaceutics-17-00173-f003" ref-type="fig">Figure 3</xref>). These results clearly indicated that NIR-AVPIT with mAb3 could eliminate viruses and virus-infected cells. </p><p>Regarding the relationship between time and antiviral effects, early treatment of infected cells with NIR-AVPIT at 7 hpi resulted in significant inhibition of FluV propagation, whereas treatment at 25 hpi showed no such effect (<xref rid="pharmaceutics-17-00173-f003" ref-type="fig">Figure 3</xref>B&#x02013;D). These results suggest that in vitro, the inhibitory effect of NIR-AVPIT on infected cells can only be achieved in the early stages of infection. In addition, NIR-AVPIT treatment had a weaker inhibitory effect against FluV-infected cells than against virions (<xref rid="pharmaceutics-17-00173-f002" ref-type="fig">Figure 2</xref> and <xref rid="pharmaceutics-17-00173-f003" ref-type="fig">Figure 3</xref>). One possible explanation for this difference could be the time-dependent expression of viral HA antigens on the surface of infected cells. Influenza A viruses begin to produce viral antigens on the cell surface approximately 6 h after inoculation [<xref rid="B37-pharmaceutics-17-00173" ref-type="bibr">37</xref>]. Therefore, NIR treatment applied at approximately 7 h after infection destroyed most infected cells, but some of the infected cells with delayed HA expression would evade antibody-binding and NIR-induced cell death. These results suggest that multiple NIR-AVPIT treatments are necessary to completely remove infected cells, including those with delayed HA expression. Indeed, in the present study, the amount of virus in the group that received two NIR-AVPIT treatments at 7 and 25 hpi was significantly reduced when compared to the amount of virus in cells that received a single treatment at 7 h post-inoculation (<xref rid="pharmaceutics-17-00173-f003" ref-type="fig">Figure 3</xref>C). </p><p>Concerning the specificity of mAb3-IR700 for infected cells in comparison to healthy cells, it is considered to be notably higher for infected cells. As shown in <xref rid="pharmaceutics-17-00173-f003" ref-type="fig">Figure 3</xref>E, mAb3 did not recognize control HEK293 cells but specifically targeted HA-expressing cells. Moreover, the data in <xref rid="pharmaceutics-17-00173-f003" ref-type="fig">Figure 3</xref>B,D demonstrated that NIR-AVPIT selectively killed FluV-infected cells while leaving uninfected cells unharmed. In assessing NIR-PIT as a therapy for cancer, it was confirmed that phototoxicity was target-specific [<xref rid="B10-pharmaceutics-17-00173" ref-type="bibr">10</xref>]. HER2 positive cells were specifically killed by anti-HER2-antibody-IR700 with NIR irradiation, but HER2 negative cells were unaffected. In addition, adverse events were minimal in NIR-PIT for oropharyngeal cancer [<xref rid="B38-pharmaceutics-17-00173" ref-type="bibr">38</xref>]. Our results and their findings support the specificity of NIR-AVPIT.</p><p>The breadth of the antibody employed in NIR-AVPIT significantly influences its effective range. Infection or vaccination chiefly induces strain-specific antibodies for the globular head of HA, but these antibodies may lose effectiveness when the virus undergoes antigenic changes in the HA head under selective pressure [<xref rid="B39-pharmaceutics-17-00173" ref-type="bibr">39</xref>]. Unlike most epitopes on the HA head, the HA stem is less permissive of amino acid substitutions and is significantly more conserved across subtypes [<xref rid="B39-pharmaceutics-17-00173" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-17-00173" ref-type="bibr">40</xref>]. Using an antibody targeting a highly conserved region for NIR-AVPIT would broaden the range of targets and enhance robustness to viral mutations. In addition, a broad-spectrum antibody would enable a reduction in the valency of NIR-AVPIT for influenza virus subtypes A/H1, A/H3, and type B. With respect to mAb3, its binding site on HA remains undetermined. Future studies are planned to investigate the epitope and assess the cross-reactivity of mAb3.</p><p>NIR-AVPIT and existing antivirals have different mechanisms to inhibit the propagation of influenza virus. A neuraminidase inhibitor such as oseltamivir blocks the release of virions from infected cells [<xref rid="B41-pharmaceutics-17-00173" ref-type="bibr">41</xref>], and a cap-dependent endonuclease inhibitor baloxavir acid inhibits viral RNA transcription [<xref rid="B42-pharmaceutics-17-00173" ref-type="bibr">42</xref>]. In NIR-AVPIT, when virions or infected cells are irradiated with NIR light, the axial ligands attached to the phthalocyanine dye IR700 dissociate by hydrolysis [<xref rid="B15-pharmaceutics-17-00173" ref-type="bibr">15</xref>]. The accumulation of such events on virions and cell membranes may lead to a loss of membrane integrity and photoimmunotherapy-associated bursting, resulting in virion destruction and cell death, making the NIR-AVPIT-based antiviral approach unique and unlike existing antiviral therapies. We consider the advantage of NIR-AVPIT over existing antivirals to be its ability to directly destroy released viruses themselves. However, a potential limitation of NIR-AVPIT appears to be the relative difficulty of NIR irradiation. Without a specialized device for NIR treatment, patients are unable to perform NIR-AVPIT at home. Since NIR-AVPIT has a mechanism of action distinct from currently approved treatments, the combination of NIR-AVPIT with existing anti-influenza drugs would be expected to exert synergistic effects. It would be particularly beneficial for the elderly or the patients with preexisting medical conditions that increase their susceptibility to influenza. </p><p>Moreover, NIR-AVPIT would also exert an indirect antiviral effect by activating host immunity similar to that activated by NIR-PIT. Previous reports have shown that NIR-PIT induces immunogenic cell death, which, unlike apoptosis, occurs rapidly [<xref rid="B9-pharmaceutics-17-00173" ref-type="bibr">9</xref>,<xref rid="B43-pharmaceutics-17-00173" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-17-00173" ref-type="bibr">44</xref>]. Molecules released by cell disruption, particularly HMGB1, are key factors in damage-associated molecular patterns (DAMPs) [<xref rid="B45-pharmaceutics-17-00173" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-17-00173" ref-type="bibr">46</xref>], suggesting that NIR-PIT and NIR-AVPIT may mediate DAMP-induced innate immune responses in vivo and promote antigen-specific immunity by targeting pathogenic viruses and virus-infected cells. NIR-AVPIT suppresses viral replication in the early stages of infection, during which time host antiviral immune mechanisms are expected to be enhanced. This study was conducted using a cell culture model and further in vivo studies are required to confirm the effects of NIR-AVPIT on immunity. </p><p>For the practical application of NIR-AVPIT in viral infections, optimal conditions for NIR-AVPIT in the early stages of infection must be established. It was reported that initiating oseltamivir treatment within 48 h of symptom onset decreased mortality [<xref rid="B47-pharmaceutics-17-00173" ref-type="bibr">47</xref>]. Considering that the effective window of oseltamivir is 48 h, it would be reasonable to evaluate the optimal timing of NIR-AVPIT administration in clinical trials starting from 48 h after symptom onset. In detecting early influenza virus infections, the sensitivity of examinations is an important factor. For diagnosis of influenza, rapid antigen testing kits based on immunochromatography are widely used; however, the sensitivity of these kits is not comparable to PCR for samples with low viral loads [<xref rid="B48-pharmaceutics-17-00173" ref-type="bibr">48</xref>]. Therefore, the development of novel kits with a higher sensitivity would contribute to earlier diagnosis of influenza. Our data suggested that multiple administration of NIR-AVPIT would be more effective than a single treatment. Designing a device that enables NIR-AVPIT to be carried out at home would facilitate repeated applications.</p><p>We evaluated NIR-AVPIT as a novel therapy against viral infections using FluV-virions and FluV-infected cells. In fact, several attempts to control viral infections by photoimmunotherapy with NIR have already been reported. However, they were intended to treat chronic retroviral infection with HIV- or HTLV-1-infected leukemic cells [<xref rid="B14-pharmaceutics-17-00173" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-17-00173" ref-type="bibr">15</xref>]. Although there has been a study using SARS-CoV-2 [<xref rid="B16-pharmaceutics-17-00173" ref-type="bibr">16</xref>], which is an acute infection, no specific studies have been reported to analyze the relationship between time after infection and antiviral efficacy. </p><p>In the present study, we showed that the combination of IR700-conjugated antibody and NIR irradiation effectively eliminated FluV virions and FluV-infected cells, indicating that the scope of this method extends beyond cancers to various types of pathogens [<xref rid="B14-pharmaceutics-17-00173" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-17-00173" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-17-00173" ref-type="bibr">16</xref>]. NIR-AVPIT can be a fast and efficient solution against a wide range of viruses and is expected to contribute to mitigating the severity of viral infections during future pandemics. </p></sec></body><back><ack><title>Acknowledgments</title><p>We are grateful to Kimi Suzuki for her help in conducting this study.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, T.M., Y.Y., N.Y. (Naoki Yamamoto). and N.Y. (Norio Yamamoto); methodology, T.M., K.T., M.T. and N.Y. (Norio Yamamoto); validation, K.T. and M.T.; formal analysis, T.M., K.T., M.T. and N.Y. (Norio Yamamoto); investigation, T.M., K.T. and N.Y. (Norio Yamamoto); resources, A.Y.; data curation, T.M., N.Y. (Naoki Yamamoto) and N.Y. (Norio Yamamoto); writing&#x02014;original draft preparation, T.M., Y.Y., A.Y., N.Y. (Naoki Yamamoto) and N.Y. (Norio Yamamoto); writing&#x02014;review and editing, T.M., Y.Y., N.Y. (Naoki Yamamoto) and N.Y. (Norio Yamamoto); visualization, N.Y. (Norio Yamamoto); supervision, Y.Y., N.Y. (Naoki Yamamoto) and N.Y. (Norio Yamamoto); project administration, N.Y. (Naoki Yamamoto) and N.Y. (Norio Yamamoto); funding acquisition, N.Y. (Norio Yamamoto). All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The animal study protocol was approved by the Institutional Review Board of Cell Engineering Corporation (protocol code: 19B07-C015, date of approval: 7 February 2019).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data are contained within the article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>K.T., M.T., Y.Y., and Norio Y. declare no conflicts of interest. T.M. and Naoki Y. are employee of Medical Corporation Koujunkai, where Aisaku Y. serves as its President. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00173"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iuliano</surname><given-names>A.D.</given-names></name>
<name><surname>Roguski</surname><given-names>K.M.</given-names></name>
<name><surname>Chang</surname><given-names>H.H.</given-names></name>
<name><surname>Muscatello</surname><given-names>D.J.</given-names></name>
<name><surname>Palekar</surname><given-names>R.</given-names></name>
<name><surname>Tempia</surname><given-names>S.</given-names></name>
<name><surname>Cohen</surname><given-names>C.</given-names></name>
<name><surname>Gran</surname><given-names>J.M.</given-names></name>
<name><surname>Schanzer</surname><given-names>D.</given-names></name>
<name><surname>Cowling</surname><given-names>B.J.</given-names></name>
<etal/>
</person-group><article-title>Estimates of global seasonal influenza-associated respiratory mortality: A modelling study</article-title><source>Lancet</source><year>2018</year><volume>391</volume><fpage>1285</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)33293-2</pub-id><pub-id pub-id-type="pmid">29248255</pub-id>
</element-citation></ref><ref id="B2-pharmaceutics-17-00173"><label>2.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Influenza (Seasonal)</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-04-07">(accessed on 7 April 2024)</date-in-citation></element-citation></ref><ref id="B3-pharmaceutics-17-00173"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Batool</surname><given-names>S.</given-names></name>
<name><surname>Chokkakula</surname><given-names>S.</given-names></name>
<name><surname>Song</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy</article-title><source>Microorganisms</source><year>2023</year><volume>11</volume><elocation-id>183</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms11010183</pub-id><pub-id pub-id-type="pmid">36677475</pub-id>
</element-citation></ref><ref id="B4-pharmaceutics-17-00173"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Erdik</surname><given-names>B.</given-names></name>
</person-group><article-title>Antiviral treatment of COVID-19 is associated with lack of immune response</article-title><source>J. Med. Virol.</source><year>2023</year><volume>95</volume><elocation-id>e28233</elocation-id><pub-id pub-id-type="doi">10.1002/jmv.28233</pub-id><pub-id pub-id-type="pmid">36257836</pub-id>
</element-citation></ref><ref id="B5-pharmaceutics-17-00173"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Corti</surname><given-names>D.</given-names></name>
<name><surname>Voss</surname><given-names>J.</given-names></name>
<name><surname>Gamblin</surname><given-names>S.J.</given-names></name>
<name><surname>Codoni</surname><given-names>G.</given-names></name>
<name><surname>Macagno</surname><given-names>A.</given-names></name>
<name><surname>Jarrossay</surname><given-names>D.</given-names></name>
<name><surname>Vachieri</surname><given-names>S.G.</given-names></name>
<name><surname>Pinna</surname><given-names>D.</given-names></name>
<name><surname>Minola</surname><given-names>A.</given-names></name>
<name><surname>Vanzetta</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins</article-title><source>Science</source><year>2011</year><volume>333</volume><fpage>850</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1126/science.1205669</pub-id><pub-id pub-id-type="pmid">21798894</pub-id>
</element-citation></ref><ref id="B6-pharmaceutics-17-00173"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ekiert</surname><given-names>D.C.</given-names></name>
<name><surname>Friesen</surname><given-names>R.H.</given-names></name>
<name><surname>Bhabha</surname><given-names>G.</given-names></name>
<name><surname>Kwaks</surname><given-names>T.</given-names></name>
<name><surname>Jongeneelen</surname><given-names>M.</given-names></name>
<name><surname>Yu</surname><given-names>W.</given-names></name>
<name><surname>Ophorst</surname><given-names>C.</given-names></name>
<name><surname>Cox</surname><given-names>F.</given-names></name>
<name><surname>Korse</surname><given-names>H.J.</given-names></name>
<name><surname>Brandenburg</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>A highly conserved neutralizing epitope on group 2 influenza A viruses</article-title><source>Science</source><year>2011</year><volume>333</volume><fpage>843</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1126/science.1204839</pub-id><pub-id pub-id-type="pmid">21737702</pub-id>
</element-citation></ref><ref id="B7-pharmaceutics-17-00173"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Okuno</surname><given-names>Y.</given-names></name>
<name><surname>Isegawa</surname><given-names>Y.</given-names></name>
<name><surname>Sasao</surname><given-names>F.</given-names></name>
<name><surname>Ueda</surname><given-names>S.</given-names></name>
</person-group><article-title>A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains</article-title><source>J. Virol.</source><year>1993</year><volume>67</volume><fpage>2552</fpage><lpage>2558</lpage><pub-id pub-id-type="doi">10.1128/jvi.67.5.2552-2558.1993</pub-id><pub-id pub-id-type="pmid">7682624</pub-id>
</element-citation></ref><ref id="B8-pharmaceutics-17-00173"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamayoshi</surname><given-names>S.</given-names></name>
<name><surname>Uraki</surname><given-names>R.</given-names></name>
<name><surname>Ito</surname><given-names>M.</given-names></name>
<name><surname>Kiso</surname><given-names>M.</given-names></name>
<name><surname>Nakatsu</surname><given-names>S.</given-names></name>
<name><surname>Yasuhara</surname><given-names>A.</given-names></name>
<name><surname>Oishi</surname><given-names>K.</given-names></name>
<name><surname>Sasaki</surname><given-names>T.</given-names></name>
<name><surname>Ikuta</surname><given-names>K.</given-names></name>
<name><surname>Kawaoka</surname><given-names>Y.</given-names></name>
</person-group><article-title>A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release</article-title><source>EBioMedicine</source><year>2017</year><volume>17</volume><fpage>182</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2017.03.007</pub-id><pub-id pub-id-type="pmid">28286060</pub-id>
</element-citation></ref><ref id="B9-pharmaceutics-17-00173"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kobayashi</surname><given-names>H.</given-names></name>
<name><surname>Choyke</surname><given-names>P.L.</given-names></name>
</person-group><article-title>Near-Infrared Photoimmunotherapy of Cancer</article-title><source>Acc. Chem. Res.</source><year>2019</year><volume>52</volume><fpage>2332</fpage><lpage>2339</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.9b00273</pub-id><pub-id pub-id-type="pmid">31335117</pub-id>
</element-citation></ref><ref id="B10-pharmaceutics-17-00173"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mitsunaga</surname><given-names>M.</given-names></name>
<name><surname>Ogawa</surname><given-names>M.</given-names></name>
<name><surname>Kosaka</surname><given-names>N.</given-names></name>
<name><surname>Rosenblum</surname><given-names>L.T.</given-names></name>
<name><surname>Choyke</surname><given-names>P.L.</given-names></name>
<name><surname>Kobayashi</surname><given-names>H.</given-names></name>
</person-group><article-title>Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules</article-title><source>Nat. Med.</source><year>2011</year><volume>17</volume><fpage>1685</fpage><lpage>1691</lpage><pub-id pub-id-type="doi">10.1038/nm.2554</pub-id><pub-id pub-id-type="pmid">22057348</pub-id>
</element-citation></ref><ref id="B11-pharmaceutics-17-00173"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohiuddin</surname><given-names>T.M.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Sheng</surname><given-names>W.</given-names></name>
<name><surname>Al-Rawe</surname><given-names>M.</given-names></name>
<name><surname>Zeppernick</surname><given-names>F.</given-names></name>
<name><surname>Meinhold-Heerlein</surname><given-names>I.</given-names></name>
<name><surname>Hussain</surname><given-names>A.F.</given-names></name>
</person-group><article-title>Near Infrared Photoimmunotherapy: A Review of Recent Progress and Their Target Molecules for Cancer Therapy</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>2655</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24032655</pub-id><pub-id pub-id-type="pmid">36768976</pub-id>
</element-citation></ref><ref id="B12-pharmaceutics-17-00173"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakajima</surname><given-names>K.</given-names></name>
<name><surname>Ogawa</surname><given-names>M.</given-names></name>
</person-group><article-title>Phototoxicity in near-infrared photoimmunotherapy is influenced by the subcellular localization of antibody-IR700</article-title><source>Photodiagnosis Photodyn. Ther.</source><year>2020</year><volume>31</volume><fpage>101926</fpage><pub-id pub-id-type="doi">10.1016/j.pdpdt.2020.101926</pub-id><pub-id pub-id-type="pmid">32717450</pub-id>
</element-citation></ref><ref id="B13-pharmaceutics-17-00173"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sato</surname><given-names>K.</given-names></name>
<name><surname>Ando</surname><given-names>K.</given-names></name>
<name><surname>Okuyama</surname><given-names>S.</given-names></name>
<name><surname>Moriguchi</surname><given-names>S.</given-names></name>
<name><surname>Ogura</surname><given-names>T.</given-names></name>
<name><surname>Totoki</surname><given-names>S.</given-names></name>
<name><surname>Hanaoka</surname><given-names>H.</given-names></name>
<name><surname>Nagaya</surname><given-names>T.</given-names></name>
<name><surname>Kokawa</surname><given-names>R.</given-names></name>
<name><surname>Takakura</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy</article-title><source>ACS Cent. Sci.</source><year>2018</year><volume>4</volume><fpage>1559</fpage><lpage>1569</lpage><pub-id pub-id-type="doi">10.1021/acscentsci.8b00565</pub-id><pub-id pub-id-type="pmid">30555909</pub-id>
</element-citation></ref><ref id="B14-pharmaceutics-17-00173"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sadraeian</surname><given-names>M.</given-names></name>
<name><surname>da Cruz</surname><given-names>E.F.</given-names></name>
<name><surname>Boyle</surname><given-names>R.W.</given-names></name>
<name><surname>Bahou</surname><given-names>C.</given-names></name>
<name><surname>Chudasama</surname><given-names>V.</given-names></name>
<name><surname>Janini</surname><given-names>L.M.R.</given-names></name>
<name><surname>Diaz</surname><given-names>R.S.</given-names></name>
<name><surname>Guimaraes</surname><given-names>F.E.G.</given-names></name>
</person-group><article-title>Photoinduced Photosensitizer-Antibody Conjugates Kill HIV Env-Expressing Cells, Also Inactivating HIV</article-title><source>ACS Omega</source><year>2021</year><volume>6</volume><fpage>16524</fpage><lpage>16534</lpage><pub-id pub-id-type="doi">10.1021/acsomega.1c01721</pub-id><pub-id pub-id-type="pmid">34235324</pub-id>
</element-citation></ref><ref id="B15-pharmaceutics-17-00173"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hatayama</surname><given-names>Y.</given-names></name>
<name><surname>Yamaoka</surname><given-names>Y.</given-names></name>
<name><surname>Morita</surname><given-names>T.</given-names></name>
<name><surname>Jeremiah</surname><given-names>S.S.</given-names></name>
<name><surname>Miyakawa</surname><given-names>K.</given-names></name>
<name><surname>Nishi</surname><given-names>M.</given-names></name>
<name><surname>Kimura</surname><given-names>Y.</given-names></name>
<name><surname>Mitsunaga</surname><given-names>M.</given-names></name>
<name><surname>Iwase</surname><given-names>T.</given-names></name>
<name><surname>Kimura</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Development of a Monoclonal Antibody Targeting HTLV-1 Envelope gp46 Glycoprotein and Its Application to Near-Infrared Photoimmuno-Antimicrobial Strategy</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>2153</elocation-id><pub-id pub-id-type="doi">10.3390/v14102153</pub-id><pub-id pub-id-type="pmid">36298708</pub-id>
</element-citation></ref><ref id="B16-pharmaceutics-17-00173"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mitsunaga</surname><given-names>M.</given-names></name>
<name><surname>Ito</surname><given-names>K.</given-names></name>
<name><surname>Nishimura</surname><given-names>T.</given-names></name>
<name><surname>Miyata</surname><given-names>H.</given-names></name>
<name><surname>Miyakawa</surname><given-names>K.</given-names></name>
<name><surname>Morita</surname><given-names>T.</given-names></name>
<name><surname>Ryo</surname><given-names>A.</given-names></name>
<name><surname>Kobayashi</surname><given-names>H.</given-names></name>
<name><surname>Mizunoe</surname><given-names>Y.</given-names></name>
<name><surname>Iwase</surname><given-names>T.</given-names></name>
</person-group><article-title>Antimicrobial strategy for targeted elimination of different microbes, including bacterial, fungal and viral pathogens</article-title><source>Commun. Biol.</source><year>2022</year><volume>5</volume><elocation-id>647</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-022-03586-4</pub-id><pub-id pub-id-type="pmid">35788695</pub-id>
</element-citation></ref><ref id="B17-pharmaceutics-17-00173"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fraser</surname><given-names>C.</given-names></name>
<name><surname>Donnelly</surname><given-names>C.A.</given-names></name>
<name><surname>Cauchemez</surname><given-names>S.</given-names></name>
<name><surname>Hanage</surname><given-names>W.P.</given-names></name>
<name><surname>Van Kerkhove</surname><given-names>M.D.</given-names></name>
<name><surname>Hollingsworth</surname><given-names>T.D.</given-names></name>
<name><surname>Griffin</surname><given-names>J.</given-names></name>
<name><surname>Baggaley</surname><given-names>R.F.</given-names></name>
<name><surname>Jenkins</surname><given-names>H.E.</given-names></name>
<name><surname>Lyons</surname><given-names>E.J.</given-names></name>
<etal/>
</person-group><article-title>Pandemic potential of a strain of influenza A (H1N1): Early findings</article-title><source>Science</source><year>2009</year><volume>324</volume><fpage>1557</fpage><lpage>1561</lpage><pub-id pub-id-type="doi">10.1126/science.1176062</pub-id><pub-id pub-id-type="pmid">19433588</pub-id>
</element-citation></ref><ref id="B18-pharmaceutics-17-00173"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Neumann</surname><given-names>G.</given-names></name>
<name><surname>Noda</surname><given-names>T.</given-names></name>
<name><surname>Kawaoka</surname><given-names>Y.</given-names></name>
</person-group><article-title>Emergence and pandemic potential of swine-origin H1N1 influenza virus</article-title><source>Nature</source><year>2009</year><volume>459</volume><fpage>931</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1038/nature08157</pub-id><pub-id pub-id-type="pmid">19525932</pub-id>
</element-citation></ref><ref id="B19-pharmaceutics-17-00173"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Kerkhove</surname><given-names>M.D.</given-names></name>
<name><surname>Vandemaele</surname><given-names>K.A.</given-names></name>
<name><surname>Shinde</surname><given-names>V.</given-names></name>
<name><surname>Jaramillo-Gutierrez</surname><given-names>G.</given-names></name>
<name><surname>Koukounari</surname><given-names>A.</given-names></name>
<name><surname>Donnelly</surname><given-names>C.A.</given-names></name>
<name><surname>Carlino</surname><given-names>L.O.</given-names></name>
<name><surname>Owen</surname><given-names>R.</given-names></name>
<name><surname>Paterson</surname><given-names>B.</given-names></name>
<name><surname>Pelletier</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: A global pooled analysis</article-title><source>PLoS Med.</source><year>2011</year><volume>8</volume><elocation-id>e1001053</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1001053</pub-id><pub-id pub-id-type="pmid">21750667</pub-id>
</element-citation></ref><ref id="B20-pharmaceutics-17-00173"><label>20.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Influenza-like Illness in the United States and Mexico, 24 April 2009</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/emergencies/disease-outbreak-news/item/2009_04_24-en" ext-link-type="uri">https://www.who.int/emergencies/disease-outbreak-news/item/2009_04_24-en</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2009-04-24">(accessed on 24 April 2009)</date-in-citation></element-citation></ref><ref id="B21-pharmaceutics-17-00173"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hamamoto</surname><given-names>I.</given-names></name>
<name><surname>Takaku</surname><given-names>H.</given-names></name>
<name><surname>Tashiro</surname><given-names>M.</given-names></name>
<name><surname>Yamamoto</surname><given-names>N.</given-names></name>
</person-group><article-title>High yield production of influenza virus in Madin Darby canine kidney (MDCK) cells with stable knockdown of IRF7</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><elocation-id>e59892</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0059892</pub-id><pub-id pub-id-type="pmid">23555825</pub-id>
</element-citation></ref><ref id="B22-pharmaceutics-17-00173"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frensing</surname><given-names>T.</given-names></name>
<name><surname>Kupke</surname><given-names>S.Y.</given-names></name>
<name><surname>Bachmann</surname><given-names>M.</given-names></name>
<name><surname>Fritzsche</surname><given-names>S.</given-names></name>
<name><surname>Gallo-Ramirez</surname><given-names>L.E.</given-names></name>
<name><surname>Reichl</surname><given-names>U.</given-names></name>
</person-group><article-title>Influenza virus intracellular replication dynamics, release kinetics, and particle morphology during propagation in MDCK cells</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2016</year><volume>100</volume><fpage>7181</fpage><lpage>7192</lpage><pub-id pub-id-type="doi">10.1007/s00253-016-7542-4</pub-id><pub-id pub-id-type="pmid">27129532</pub-id>
</element-citation></ref><ref id="B23-pharmaceutics-17-00173"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burley</surname><given-names>T.A.</given-names></name>
<name><surname>Maczynska</surname><given-names>J.</given-names></name>
<name><surname>Shah</surname><given-names>A.</given-names></name>
<name><surname>Szopa</surname><given-names>W.</given-names></name>
<name><surname>Harrington</surname><given-names>K.J.</given-names></name>
<name><surname>Boult</surname><given-names>J.K.R.</given-names></name>
<name><surname>Mrozek-Wilczkiewicz</surname><given-names>A.</given-names></name>
<name><surname>Vinci</surname><given-names>M.</given-names></name>
<name><surname>Bamber</surname><given-names>J.C.</given-names></name>
<name><surname>Kaspera</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment</article-title><source>Int. J. Cancer</source><year>2018</year><volume>142</volume><fpage>2363</fpage><lpage>2374</lpage><pub-id pub-id-type="doi">10.1002/ijc.31246</pub-id><pub-id pub-id-type="pmid">29313975</pub-id>
</element-citation></ref><ref id="B24-pharmaceutics-17-00173"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nagaya</surname><given-names>T.</given-names></name>
<name><surname>Sato</surname><given-names>K.</given-names></name>
<name><surname>Harada</surname><given-names>T.</given-names></name>
<name><surname>Nakamura</surname><given-names>Y.</given-names></name>
<name><surname>Choyke</surname><given-names>P.L.</given-names></name>
<name><surname>Kobayashi</surname><given-names>H.</given-names></name>
</person-group><article-title>Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0136829</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0136829</pub-id><pub-id pub-id-type="pmid">26313651</pub-id>
</element-citation></ref><ref id="B25-pharmaceutics-17-00173"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamaguchi</surname><given-names>H.</given-names></name>
<name><surname>On</surname><given-names>J.</given-names></name>
<name><surname>Morita</surname><given-names>T.</given-names></name>
<name><surname>Suzuki</surname><given-names>T.</given-names></name>
<name><surname>Okada</surname><given-names>Y.</given-names></name>
<name><surname>Ono</surname><given-names>J.</given-names></name>
<name><surname>Evdokiou</surname><given-names>A.</given-names></name>
</person-group><article-title>Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>2213</elocation-id><pub-id pub-id-type="doi">10.3390/ijms222212213</pub-id><pub-id pub-id-type="pmid">33672304</pub-id>
</element-citation></ref><ref id="B26-pharmaceutics-17-00173"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakamura</surname><given-names>Y.</given-names></name>
<name><surname>Ohler</surname><given-names>Z.W.</given-names></name>
<name><surname>Householder</surname><given-names>D.</given-names></name>
<name><surname>Nagaya</surname><given-names>T.</given-names></name>
<name><surname>Sato</surname><given-names>K.</given-names></name>
<name><surname>Okuyama</surname><given-names>S.</given-names></name>
<name><surname>Ogata</surname><given-names>F.</given-names></name>
<name><surname>Daar</surname><given-names>D.</given-names></name>
<name><surname>Hoa</surname><given-names>T.</given-names></name>
<name><surname>Choyke</surname><given-names>P.L.</given-names></name>
<etal/>
</person-group><article-title>Near Infrared Photoimmunotherapy in a Transgenic Mouse Model of Spontaneous Epidermal Growth Factor Receptor (EGFR)-expressing Lung Cancer</article-title><source>Mol. Cancer Ther.</source><year>2017</year><volume>16</volume><fpage>408</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-16-0663</pub-id><pub-id pub-id-type="pmid">28151706</pub-id>
</element-citation></ref><ref id="B27-pharmaceutics-17-00173"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sato</surname><given-names>K.</given-names></name>
<name><surname>Nagaya</surname><given-names>T.</given-names></name>
<name><surname>Choyke</surname><given-names>P.L.</given-names></name>
<name><surname>Kobayashi</surname><given-names>H.</given-names></name>
</person-group><article-title>Near infrared photoimmunotherapy in the treatment of pleural disseminated NSCLC: Preclinical experience</article-title><source>Theranostics</source><year>2015</year><volume>5</volume><fpage>698</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.7150/thno.11559</pub-id><pub-id pub-id-type="pmid">25897335</pub-id>
</element-citation></ref><ref id="B28-pharmaceutics-17-00173"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hanaoka</surname><given-names>H.</given-names></name>
<name><surname>Nagaya</surname><given-names>T.</given-names></name>
<name><surname>Sato</surname><given-names>K.</given-names></name>
<name><surname>Nakamura</surname><given-names>Y.</given-names></name>
<name><surname>Watanabe</surname><given-names>R.</given-names></name>
<name><surname>Harada</surname><given-names>T.</given-names></name>
<name><surname>Gao</surname><given-names>W.</given-names></name>
<name><surname>Feng</surname><given-names>M.</given-names></name>
<name><surname>Phung</surname><given-names>Y.</given-names></name>
<name><surname>Kim</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy</article-title><source>Mol. Pharm.</source><year>2015</year><volume>12</volume><fpage>2151</fpage><lpage>2157</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.5b00132</pub-id><pub-id pub-id-type="pmid">25955255</pub-id>
</element-citation></ref><ref id="B29-pharmaceutics-17-00173"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maawy</surname><given-names>A.A.</given-names></name>
<name><surname>Hiroshima</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Garcia-Guzman</surname><given-names>M.</given-names></name>
<name><surname>Luiken</surname><given-names>G.A.</given-names></name>
<name><surname>Kobayashi</surname><given-names>H.</given-names></name>
<name><surname>Hoffman</surname><given-names>R.M.</given-names></name>
<name><surname>Bouvet</surname><given-names>M.</given-names></name>
</person-group><article-title>Photoimmunotherapy lowers recurrence after pancreatic cancer surgery in orthotopic nude mouse models</article-title><source>J. Surg. Res.</source><year>2015</year><volume>197</volume><fpage>5</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2015.02.037</pub-id><pub-id pub-id-type="pmid">25799527</pub-id>
</element-citation></ref><ref id="B30-pharmaceutics-17-00173"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nishimura</surname><given-names>T.</given-names></name>
<name><surname>Mitsunaga</surname><given-names>M.</given-names></name>
<name><surname>Sawada</surname><given-names>R.</given-names></name>
<name><surname>Saruta</surname><given-names>M.</given-names></name>
<name><surname>Kobayashi</surname><given-names>H.</given-names></name>
<name><surname>Matsumoto</surname><given-names>N.</given-names></name>
<name><surname>Kanke</surname><given-names>T.</given-names></name>
<name><surname>Yanai</surname><given-names>H.</given-names></name>
<name><surname>Nakamura</surname><given-names>K.</given-names></name>
</person-group><article-title>Photoimmunotherapy targeting biliary-pancreatic cancer with humanized anti-TROP2 antibody</article-title><source>Cancer Med.</source><year>2019</year><volume>8</volume><fpage>7781</fpage><lpage>7792</lpage><pub-id pub-id-type="doi">10.1002/cam4.2658</pub-id><pub-id pub-id-type="pmid">31674732</pub-id>
</element-citation></ref><ref id="B31-pharmaceutics-17-00173"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nagaya</surname><given-names>T.</given-names></name>
<name><surname>Nakamura</surname><given-names>Y.</given-names></name>
<name><surname>Okuyama</surname><given-names>S.</given-names></name>
<name><surname>Ogata</surname><given-names>F.</given-names></name>
<name><surname>Maruoka</surname><given-names>Y.</given-names></name>
<name><surname>Choyke</surname><given-names>P.L.</given-names></name>
<name><surname>Kobayashi</surname><given-names>H.</given-names></name>
</person-group><article-title>Near-Infrared Photoimmunotherapy Targeting Prostate Cancer with Prostate-Specific Membrane Antigen (PSMA) Antibody</article-title><source>Mol. Cancer Res.</source><year>2017</year><volume>15</volume><fpage>1153</fpage><lpage>1162</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-17-0164</pub-id><pub-id pub-id-type="pmid">28588059</pub-id>
</element-citation></ref><ref id="B32-pharmaceutics-17-00173"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nagaya</surname><given-names>T.</given-names></name>
<name><surname>Okuyama</surname><given-names>S.</given-names></name>
<name><surname>Ogata</surname><given-names>F.</given-names></name>
<name><surname>Maruoka</surname><given-names>Y.</given-names></name>
<name><surname>Knapp</surname><given-names>D.W.</given-names></name>
<name><surname>Karagiannis</surname><given-names>S.N.</given-names></name>
<name><surname>Fazekas-Singer</surname><given-names>J.</given-names></name>
<name><surname>Choyke</surname><given-names>P.L.</given-names></name>
<name><surname>LeBlanc</surname><given-names>A.K.</given-names></name>
<name><surname>Jensen-Jarolim</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>19026</fpage><lpage>19038</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.24876</pub-id><pub-id pub-id-type="pmid">29721181</pub-id>
</element-citation></ref><ref id="B33-pharmaceutics-17-00173"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Inagaki</surname><given-names>F.F.</given-names></name>
<name><surname>Wakiyama</surname><given-names>H.</given-names></name>
<name><surname>Furusawa</surname><given-names>A.</given-names></name>
<name><surname>Okada</surname><given-names>R.</given-names></name>
<name><surname>Kato</surname><given-names>T.</given-names></name>
<name><surname>Fujimura</surname><given-names>D.</given-names></name>
<name><surname>Okuyama</surname><given-names>S.</given-names></name>
<name><surname>Fukushima</surname><given-names>H.</given-names></name>
<name><surname>Takao</surname><given-names>S.</given-names></name>
<name><surname>Choyke</surname><given-names>P.L.</given-names></name>
<etal/>
</person-group><article-title>Near-infrared photoimmunotherapy (NIR-PIT) of bone metastases</article-title><source>Biomed. Pharmacother.</source><year>2023</year><volume>160</volume><elocation-id>114390</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2023.114390</pub-id><pub-id pub-id-type="pmid">36791566</pub-id>
</element-citation></ref><ref id="B34-pharmaceutics-17-00173"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sato</surname><given-names>K.</given-names></name>
<name><surname>Nagaya</surname><given-names>T.</given-names></name>
<name><surname>Mitsunaga</surname><given-names>M.</given-names></name>
<name><surname>Choyke</surname><given-names>P.L.</given-names></name>
<name><surname>Kobayashi</surname><given-names>H.</given-names></name>
</person-group><article-title>Near infrared photoimmunotherapy for lung metastases</article-title><source>Cancer Lett.</source><year>2015</year><volume>365</volume><fpage>112</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2015.05.018</pub-id><pub-id pub-id-type="pmid">26021765</pub-id>
</element-citation></ref><ref id="B35-pharmaceutics-17-00173"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mendoza</surname><given-names>M.</given-names></name>
<name><surname>Ballesteros</surname><given-names>A.</given-names></name>
<name><surname>Qiu</surname><given-names>Q.</given-names></name>
<name><surname>Pow Sang</surname><given-names>L.</given-names></name>
<name><surname>Shashikumar</surname><given-names>S.</given-names></name>
<name><surname>Casares</surname><given-names>S.</given-names></name>
<name><surname>Brumeanu</surname><given-names>T.D.</given-names></name>
</person-group><article-title>Generation and testing anti-influenza human monoclonal antibodies in a new humanized mouse model (DRAGA: HLA-A2. HLA-DR4. Rag1 KO. IL-2Rgammac KO. NOD)</article-title><source>Hum. Vaccin. Immunother.</source><year>2018</year><volume>14</volume><fpage>345</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1403703</pub-id><pub-id pub-id-type="pmid">29135340</pub-id>
</element-citation></ref><ref id="B36-pharmaceutics-17-00173"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salazar</surname><given-names>G.</given-names></name>
<name><surname>Zhang</surname><given-names>N.</given-names></name>
<name><surname>Fu</surname><given-names>T.M.</given-names></name>
<name><surname>An</surname><given-names>Z.</given-names></name>
</person-group><article-title>Antibody therapies for the prevention and treatment of viral infections</article-title><source>NPJ Vaccines</source><year>2017</year><volume>2</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.1038/s41541-017-0019-3</pub-id><pub-id pub-id-type="pmid">29263875</pub-id>
</element-citation></ref><ref id="B37-pharmaceutics-17-00173"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Einav</surname><given-names>T.</given-names></name>
<name><surname>Gentles</surname><given-names>L.E.</given-names></name>
<name><surname>Bloom</surname><given-names>J.D.</given-names></name>
</person-group><article-title>SnapShot: Influenza by the Numbers</article-title><source>Cell</source><year>2020</year><volume>182</volume><fpage>532</fpage><lpage>532.e1</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.05.004</pub-id><pub-id pub-id-type="pmid">32707094</pub-id>
</element-citation></ref><ref id="B38-pharmaceutics-17-00173"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nishikawa</surname><given-names>D.</given-names></name>
<name><surname>Suzuki</surname><given-names>H.</given-names></name>
<name><surname>Beppu</surname><given-names>S.</given-names></name>
<name><surname>Terada</surname><given-names>H.</given-names></name>
<name><surname>Sawabe</surname><given-names>M.</given-names></name>
<name><surname>Hanai</surname><given-names>N.</given-names></name>
</person-group><article-title>Near-Infrared Photoimmunotherapy for Oropharyngeal Cancer</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>5662</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14225662</pub-id><pub-id pub-id-type="pmid">36428754</pub-id>
</element-citation></ref><ref id="B39-pharmaceutics-17-00173"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zost</surname><given-names>S.J.</given-names></name>
<name><surname>Wu</surname><given-names>N.C.</given-names></name>
<name><surname>Hensley</surname><given-names>S.E.</given-names></name>
<name><surname>Wilson</surname><given-names>I.A.</given-names></name>
</person-group><article-title>Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens</article-title><source>J. Infect. Dis.</source><year>2019</year><volume>219</volume><fpage>S38</fpage><lpage>S45</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy696</pub-id><pub-id pub-id-type="pmid">30535315</pub-id>
</element-citation></ref><ref id="B40-pharmaceutics-17-00173"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doud</surname><given-names>M.B.</given-names></name>
<name><surname>Lee</surname><given-names>J.M.</given-names></name>
<name><surname>Bloom</surname><given-names>J.D.</given-names></name>
</person-group><article-title>How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>1386</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-03665-3</pub-id><pub-id pub-id-type="pmid">29643370</pub-id>
</element-citation></ref><ref id="B41-pharmaceutics-17-00173"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gubareva</surname><given-names>L.V.</given-names></name>
<name><surname>Kaiser</surname><given-names>L.</given-names></name>
<name><surname>Hayden</surname><given-names>F.G.</given-names></name>
</person-group><article-title>Influenza virus neuraminidase inhibitors</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>827</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(99)11433-8</pub-id><pub-id pub-id-type="pmid">10711940</pub-id>
</element-citation></ref><ref id="B42-pharmaceutics-17-00173"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Noshi</surname><given-names>T.</given-names></name>
<name><surname>Kitano</surname><given-names>M.</given-names></name>
<name><surname>Taniguchi</surname><given-names>K.</given-names></name>
<name><surname>Yamamoto</surname><given-names>A.</given-names></name>
<name><surname>Omoto</surname><given-names>S.</given-names></name>
<name><surname>Baba</surname><given-names>K.</given-names></name>
<name><surname>Hashimoto</surname><given-names>T.</given-names></name>
<name><surname>Ishida</surname><given-names>K.</given-names></name>
<name><surname>Kushima</surname><given-names>Y.</given-names></name>
<name><surname>Hattori</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit</article-title><source>Antivir. Res.</source><year>2018</year><volume>160</volume><fpage>109</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2018.10.008</pub-id><pub-id pub-id-type="pmid">30316915</pub-id>
</element-citation></ref><ref id="B43-pharmaceutics-17-00173"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kobayashi</surname><given-names>H.</given-names></name>
<name><surname>Furusawa</surname><given-names>A.</given-names></name>
<name><surname>Rosenberg</surname><given-names>A.</given-names></name>
<name><surname>Choyke</surname><given-names>P.L.</given-names></name>
</person-group><article-title>Near-infrared photoimmunotherapy of cancer: A new approach that kills cancer cells and enhances anti-cancer host immunity</article-title><source>Int. Immunol.</source><year>2021</year><volume>33</volume><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxaa037</pub-id><pub-id pub-id-type="pmid">32496557</pub-id>
</element-citation></ref><ref id="B44-pharmaceutics-17-00173"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ogawa</surname><given-names>M.</given-names></name>
<name><surname>Tomita</surname><given-names>Y.</given-names></name>
<name><surname>Nakamura</surname><given-names>Y.</given-names></name>
<name><surname>Lee</surname><given-names>M.J.</given-names></name>
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>Tomita</surname><given-names>S.</given-names></name>
<name><surname>Nagaya</surname><given-names>T.</given-names></name>
<name><surname>Sato</surname><given-names>K.</given-names></name>
<name><surname>Yamauchi</surname><given-names>T.</given-names></name>
<name><surname>Iwai</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>10425</fpage><lpage>10436</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.14425</pub-id><pub-id pub-id-type="pmid">28060726</pub-id>
</element-citation></ref><ref id="B45-pharmaceutics-17-00173"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kono</surname><given-names>H.</given-names></name>
<name><surname>Rock</surname><given-names>K.L.</given-names></name>
</person-group><article-title>How dying cells alert the immune system to danger</article-title><source>Nat. Rev. Immunol.</source><year>2008</year><volume>8</volume><fpage>279</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1038/nri2215</pub-id><pub-id pub-id-type="pmid">18340345</pub-id>
</element-citation></ref><ref id="B46-pharmaceutics-17-00173"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zitvogel</surname><given-names>L.</given-names></name>
<name><surname>Kepp</surname><given-names>O.</given-names></name>
<name><surname>Kroemer</surname><given-names>G.</given-names></name>
</person-group><article-title>Decoding cell death signals in inflammation and immunity</article-title><source>Cell</source><year>2010</year><volume>140</volume><fpage>798</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.02.015</pub-id><pub-id pub-id-type="pmid">20303871</pub-id>
</element-citation></ref><ref id="B47-pharmaceutics-17-00173"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adlhoch</surname><given-names>C.</given-names></name>
<name><surname>Delgado-Sanz</surname><given-names>C.</given-names></name>
<name><surname>Carnahan</surname><given-names>A.</given-names></name>
<name><surname>Larrauri</surname><given-names>A.</given-names></name>
<name><surname>Popovici</surname><given-names>O.</given-names></name>
<name><surname>Bossuyt</surname><given-names>N.</given-names></name>
<name><surname>Thomas</surname><given-names>I.</given-names></name>
<name><surname>Kyncl</surname><given-names>J.</given-names></name>
<name><surname>Slezak</surname><given-names>P.</given-names></name>
<name><surname>Brytting</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020</article-title><source>J. Infect. Dis.</source><year>2023</year><volume>28</volume><fpage>356</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2023.28.4.2200340</pub-id></element-citation></ref><ref id="B48-pharmaceutics-17-00173"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dinc</surname><given-names>H.O.</given-names></name>
<name><surname>Karabulut</surname><given-names>N.</given-names></name>
<name><surname>Alacam</surname><given-names>S.</given-names></name>
<name><surname>Uysal</surname><given-names>H.K.</given-names></name>
<name><surname>Dasdemir</surname><given-names>F.O.</given-names></name>
<name><surname>Onel</surname><given-names>M.</given-names></name>
<name><surname>Tuyji Tok</surname><given-names>Y.</given-names></name>
<name><surname>Sirekbasan</surname><given-names>S.</given-names></name>
<name><surname>Agacfidan</surname><given-names>A.</given-names></name>
<name><surname>Gareayaghi</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Evaluation of the Diagnostic Performance of a SARS-CoV-2 and Influenza A/B Combo Rapid Antigen Test in Respiratory Samples</article-title><source>Diagnostics</source><year>2023</year><volume>13</volume><elocation-id>972</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics13050972</pub-id><pub-id pub-id-type="pmid">36900116</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-00173-f001"><label>Figure 1</label><caption><p>Selection of anti-HA antibody without neutralizing activity. (<bold>A</bold>) Neutralization activity was assessed for the three monoclonal antibodies (mAb1, mAb2, and mAb3) based on their cytopathic effect (CPE). The antibody concentrations tested were 1 &#x000b5;g/mL and 10 &#x000b5;g/mL. Cell morphology was analyzed by optical microscopy. Scale bar = 100 &#x000b5;m. (i) no virus/no antibody, (ii) FluV/no antibody, (iii) FluV/control IgG (10 &#x000b5;g/mL), (iv) FluV/mAb1 (10 &#x000b5;g/mL), (v) FluV/mAb2 (10 &#x000b5;g/mL), (vi) FluV/mAb3 (10 &#x000b5;g/mL), (vii) FluV/mAb1 (1 &#x000b5;g/mL), (viii) FluV/mAb2 (1 &#x000b5;g/mL), (ix) FluV/mAb3 (1 &#x000b5;g/mL). (<bold>B</bold>) The amounts of viral RNA propagated in the culture of MDCK cells during 48 h incubation. The relative viral RNA quantities were measured by RT-qPCR. The data are expressed as the mean&#x02009; &#x000b1; SD from three independent experiments. Asterisks indicate statistically significant differences when compared with the control cells. * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01.</p></caption><graphic xlink:href="pharmaceutics-17-00173-g001" position="float"/></fig><fig position="float" id="pharmaceutics-17-00173-f002"><label>Figure 2</label><caption><p>Direct inactivation of FluV particles by NIR-AVPIT. (<bold>A</bold>) Schematic diagram of the experiment used to evaluate the direct effect of NIR-AVPIT on FluV virions. (<bold>B</bold>) Representative images of CPE in MDCK cells 48 h after FluV inoculation. Scale bar = 100 &#x000b5;m. (i) no antibody/no irradiation, (ii) mAb3-IR700/no irradiation, (iii) no antibody/NIR irradiation, (iv) mAb3-IR700/NIR irradiation. (<bold>C</bold>) The amounts of viral RNA amplified in the culture of MDCK cells during 48 h incubation. The relative viral RNA quantities were measured by RT-qPCR. The experiments were repeated independently at least three times with good reproducibility. The data are shown as the mean &#x02009;&#x000b1; SD. Asterisks indicate statistically significant differences when compared with the control cells. * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01.</p></caption><graphic xlink:href="pharmaceutics-17-00173-g002" position="float"/></fig><fig position="float" id="pharmaceutics-17-00173-f003"><label>Figure 3</label><caption><p>Effect of NIR-AVPIT on virus infected cells and HA-expressing cells. (<bold>A</bold>) Schematic diagram of the experiments to evaluate the effect of single or double NIR-AVPIT on FluV-infected cells. (<bold>B</bold>) Microscopic observation of MDCK cells with or without NIR-AVPIT 48 h after virus inoculation. FluV-infected cells were treated with single (at 7 or 25 hpi) or double (at 7 and 25 hpi) NIR-AVPIT. (i) no antibody/no irradiation, (ii) mAb3-IR700 (24 hpi)/no irradiation, (iii) no antibody/NIR irradiation (25 hpi), (iv) mAb3-IR700 (24 hpi)/NIR irradiation (25 hpi), (v) mAb3-IR700 (6 hpi)/NIR irradiation (7 hpi), (vi) mAb3-IR700 (6 and 24 hpi)/NIR irradiation (7 and 25 hpi). (<bold>C</bold>) The amounts of viral RNA produced from the infected MDCK cells with or without NIR-AVPIT at 24 or 48 hpi. The relative viral RNA quantities were measured by RT-qPCR. These data were obtained from three independent experiments and are presented as the mean&#x02009;&#x000b1; SD. Asterisks indicate statistically significant differences with <italic toggle="yes">p</italic> &#x0003c; 0.05. (<bold>D</bold>) The viability of FluV-infected cells with or without NIR-AVPIT treatment. At 48 hpi, the viability of MDCK cells was evaluated by MTS assay. Results are shown as the mean &#x000b1; SD from three independent experiments. Asterisks indicate statistically significant differences with * <italic toggle="yes">p</italic> &#x0003c; 0.05. (<bold>E</bold>) Selection of HA-expressing HEK293 clones by FACS analysis. Blue, control 293 cells (no HA expression); black, 293-HA clone 1; green, 293-HA clone 2; and magenta, 293-HA clone 3. The expression level of HA is the highest in 293-HA clone 3. (<bold>F</bold>) Representative micrographs of 293-HA clone 3 cells with or without NIR-AVPIT. Cell morphology was observed 1 h before NIR treatment and 1.5 h and 24 h after NIR treatment. (i) no antibody/1 h before NIR, (ii) no antibody/1.5 h after NIR, (iii) no antibody/24 h after NIR, (iv) mAb3-IR700/1 h before NIR, (v) mAb3-IR700/1.5 h after NIR, (vi) mAb3-IR700/24 h after NIR.</p></caption><graphic xlink:href="pharmaceutics-17-00173-g003" position="float"/></fig></floats-group></article>